FIGURE 1.
Time courses for daily insulin dose, HbA1c and clinic FPG for people with Type 2 diabetes starting insulin while continuing rosiglitazone + metformin (□) or transferring to placebo (•). Data are mean ± se for ITT populations with LOCF, except for dose which is without LOCF. For statistical significance see Results and Table 2.